T2 Biosystems, Inc. (TTOO)

NASDAQ: TTOO · IEX Real-Time Price · USD
3.000
+0.010 (0.33%)
Apr 19, 2024, 2:30 PM EDT - Market open
0.33%
Market Cap 16.47M
Revenue (ttm) 7.19M
Net Income (ttm) -50.08M
Shares Out 5.51M
EPS (ttm) -19.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 27,678
Open 3.010
Previous Close 2.990
Day's Range 2.920 - 3.070
52-Week Range 2.700 - 70.000
Beta 0.10
Analysts Hold
Price Target 7.00 (+133.33%)
Earnings Date May 13, 2024

About TTOO

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood st... [Read more]

Sector Healthcare
IPO Date Aug 7, 2014
Employees 113
Stock Exchange NASDAQ
Ticker Symbol TTOO
Full Company Profile

Financial Performance

In 2023, T2 Biosystems's revenue was $7.19 million, a decrease of -67.75% compared to the previous year's $22.31 million. Losses were -$50.08 million, -19.66% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for TTOO stock is "Hold" and the 12-month stock price forecast is $7.0.

Price Target
$7.0
(133.33% upside)
Analyst Consensus: Hold
Stock Forecasts

News

T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity

LEXINGTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced res...

7 days ago - GlobeNewsWire

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

LEXINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced tha...

22 days ago - GlobeNewsWire

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024 Anticipates commercial launch of the T2Lyme Panel in the third quarter of 2024

4 weeks ago - GlobeNewsWire

T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates

LEXINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, tod...

4 weeks ago - GlobeNewsWire

T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel

Study demonstrates T2Resistance Panel utilization enables faster targeted therapy based on direct-from-blood detection of resistance genes Study demonstrates T2Resistance Panel utilization enables fas...

4 weeks ago - GlobeNewsWire

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

LEXINGTON, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced tha...

5 weeks ago - GlobeNewsWire

T2 Biosystems (TTOO) share price stays stable post Q4 earnings

T2 Biosystems Inc. (TTOO), a prominent player in the field of medical diagnostics, recently announced its financial results for the fourth quarter of 2023, signaling a pivotal moment for the company.

2 months ago - Invezz

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results

Advanced multiple new products and achieved record fourth quarter U.S. T2Bacteria Panel sales Advanced multiple new products and achieved record fourth quarter U.S. T2Bacteria Panel sales

2 months ago - GlobeNewsWire

T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity

LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the ...

2 months ago - GlobeNewsWire

T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia

LEXINGTON, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the e...

2 months ago - GlobeNewsWire

T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel

Increases number of bacteria species detected with addition of Acinetobacter baumannii Increases number of bacteria species detected with addition of Acinetobacter baumannii

2 months ago - GlobeNewsWire

T2 BioSystems stock: brace for TTOO volatility this week

T2 BioSystems (NASDAQ: TTOO) stock price has moved from one of the most popular names in Wall Street into a forgotten one. The shares have gone nowhere since October and are now sitting near their low...

2 months ago - Invezz

T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024

LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that...

2 months ago - GlobeNewsWire

U.S. Department of Health and Human Services and Steven and Alexandra Cohen Foundation Name T2 Biosystems a Phase 2 Winner in the LymeX Diagnostics Prize

LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that ...

2 months ago - GlobeNewsWire

T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia Patients

LEXINGTON, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced part...

3 months ago - GlobeNewsWire

T2 Biosystems Announces FDA 510(k) Submission to Expand Use of the FDA-Cleared T2Candida Panel to Include Pediatric Testing

LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that...

3 months ago - GlobeNewsWire

What's going on with T2 Biosystems (TTOO) stock?

T2 BioSystems (NASDAQ: TTOO) stock price rose by more than 23% on Tuesday amid a short-squeeze and as some investors bought the dip. The shares jumped to a high of $4.81, its highest point sice mid-No...

4 months ago - Invezz

T2 Biosystems (TTOO) stock price volatility has died: buy the dip?

T2 Biosystems (NASDAQ: TTOO) stock price has collapsed to a record low as concerns about the company's future continued. Shares of the popular penny stock have collapsed to a split-adjusted low of $4....

5 months ago - Invezz

T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

LEXINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, toda...

6 months ago - GlobeNewsWire

T2 Biosystems Regains Compliance with Nasdaq Listing Requirements

LEXINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, toda...

6 months ago - GlobeNewsWire

T2 Biosystems Highlights New Clinical Data Presented at IDWeek 2023 Conference

Data demonstrates speed, accuracy, and clinical benefits of the T2Dx Instrument and T2 Biosystems' sepsis panels, including encouraging early detection data for T2Resistance Panel Data demonstrates sp...

6 months ago - GlobeNewsWire

T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement

LEXINGTON, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the s...

6 months ago - GlobeNewsWire

T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and Business Updates

Received FDA 510(k) clearance for the T2Biothreat Panel and significantly strengthened balance sheet Received FDA 510(k) clearance for the T2Biothreat Panel and significantly strengthened balance shee...

6 months ago - GlobeNewsWire

T2 Biosystems Announces FDA 510(k) Submission to Expand the Pathogen Detection on its FDA-Cleared T2Bacteria Panel to Include Detection of Acinetobacter baumannii

LEXINGTON, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that...

6 months ago - GlobeNewsWire

T2 Biosystems Announces Reverse Stock Split Effective Today

TTOO common stock expected to begin trading on a split-adjusted basis on October 13, 2023 TTOO common stock expected to begin trading on a split-adjusted basis on October 13, 2023

6 months ago - GlobeNewsWire